Senior Data Engineer
About the job
- At least 5 years of data engineering experience, including at least 2 years focused on distributed, large-scale cloud data warehouses.
- Proven experience optimizing Snowflake performance and governing costs.
- Deep proficiency in Python, including writing modular, reusable, and testable code and unit and integration tests for complex data processing.
- Expert-level SQL and a sophisticated understanding of data warehousing methodologies for building performant, scalable analytics layers.
- Practical experience with modern CI/CD frameworks such as GitHub Actions or Argo CD.
- Expertise architecting and scaling orchestration-as-code workflows such as Prefect or Airflow to manage complex dependencies and ensure pipeline resilience.
- Deep proficiency deploying monitoring and alerting frameworks such as Datadog to maximize uptime while mitigating alert fatigue.
- Experience managing business-critical production pipelines with a focus on uptime, data quality, and defining SLAs.
- A BS or MS in Computer Science, Information Systems, or a related technical field.
- Develop core Looker views and build agentic AI infrastructure to enable automated self-service capabilities and reduce reporting bottlenecks.
- Design, build, and scale resilient, efficient, and modular ELT pipelines.
- Partner with Finance, Product, and Analytics to ensure data models address the right problems.
- Build and maintain analytics schemas, including star schemas, that abstract complex logic into user-friendly datasets.
- Lead projects from inception to production and take accountability for data integrity and platform trustworthiness.
- Monitor production health using tools such as Datadog and Monte Carlo to keep the data ecosystem robust and reliable.
- Act as a technical lead, conduct code reviews, define engineering culture, and champion best practices.
- Familiarity with Snowflake Cortex or MCP.
About the company
Weight Watchers runs a weight management program centered on group support and accountability. Members join meetings for guidance, share tips, and track progress as part of a community that helps people manage eating and activity habits rather than promoting a single diet. The program typically involves paying a weekly or regular fee for in-person or virtual meetings, plus related products and materials that support behavior change. It differentiates itself from competitors by emphasizing a social, ongoing support system and a structured points-based approach to eating that members follow within a community framework, rather than relying on short-term diet plans. The company’s goal is to help people achieve healthier weight and lifestyles through long-term, sustainable changes supported by a network of peers and coaches.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
1963
Get referred to Weight Watchers
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 clinical subscribers reached 197,000, up 55.7% year over year.
- Clinical revenue rose 30.4% to $39.9 million, now 24.6% of sales.
- Debt fell to $423.6 million after $36.8 million Q2 prepayments.
What critics are saying
- Core subscribers keep shrinking, and total subscribers fell 24.6% in Q2 2026.
- Tara Comonte resigned April 2026; Stephen Bye inherits another transition during recovery.
- If clinical growth stalls, WeightWatchers' remaining debt service and legacy decline crush the franchise.
What makes Weight Watchers unique
- Stephen Bye, ex-Ookla, brings subscription turnaround expertise to WeightWatchers’ clinical-plus-behavioral platform.
- Med+ integrates clinicians, GLP-1 access, insurance navigation, and coaching under one brand.
- Core+ and clinical offerings deepen ARPU versus the collapsing Core legacy tier.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Flexible Work Hours
Hybrid Work Options
Company News
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Weight Watchers has appointed Stephen Bye as president and chief executive officer, effective this autumn. Bye previously served as CEO of Ookla, a connectivity intelligence company, where he transformed the subscription business and improved profitability whilst leading multiple acquisitions. Gene Davis, chairman of Weight Watchers' board, cited Bye's track record of growing subscription businesses and creating shareholder value. The board conducted an extensive search prioritising proven CEO leadership and experience in consumer subscription businesses. Bye brings over 30 years of leadership experience in consumer technology businesses. He has held senior roles at DISH Network, Connectivity Wireless, C Spire, and Sprint, where he served as chief technology officer. Weight Watchers is building an integrated weight health platform combining behavioural approaches, clinical care, and access to GLP-1 medications with technology-driven personalisation.
WeightWatchers reported Q2 revenues of $162.3 million, down 14.2% year-on-year but exceeding analyst expectations by 2%. The wellness company beat EPS estimates but missed EBITDA projections in what was deemed a satisfactory quarter. Despite the relatively good results, WeightWatchers delivered the weakest full-year guidance update among nine consumer discretionary specialised consumer services stocks tracked. The sector as a whole underperformed in Q2, with revenues missing consensus estimates by 0.7%. The market reacted negatively to WeightWatchers' outlook. Shares fell 8.4% following the earnings announcement and currently trade at $14.12. Consumer discretionary specialised consumer services stocks have declined 4.6% on average since their latest earnings results.
WeightWatchers reported second-quarter revenue of $162.3 million, beating analyst estimates of $159.1 million despite a 14.2% year-on-year decline. The company posted earnings per share of $1.41, significantly above the $0.67 estimate. Management highlighted a strategic shift towards higher-value membership tiers and clinical offerings, with growth in Core+ and Med+ subscribers offsetting declines in traditional behavioural segments. Interim Chief Operations Officer Jonathan Volkmann noted the company's approach combines FDA-approved GLP-1 medications with expert guidance. The company reaffirmed full-year revenue guidance of $627.5 million and EBITDA guidance of $110 million. Operating margin fell to 8.1% from 28.1% in the prior year quarter. No analyst question-and-answer session occurred during the earnings call.
WW International reported Q2 2026 revenue of $162.3 million, down from $189.2 million the previous year. Clinical subscription revenue grew 30.4% year-over-year to $39.9 million, now representing 24.6% of total revenue. Clinical subscribers reached 197,000, up 55.7% annually. The company's Core+ tier showed momentum with 541,000 subscribers, up 13.9% year-over-year, marking three consecutive quarters of sequential growth. However, total subscribers fell 24.6% to 2.3 million due to weakness in the Core tier. WW reported net income of $14.1 million and adjusted EBITDA of $39.8 million with a 24.5% margin. The company generated $24.3 million in operating cash flow and reduced its term loan to $423.6 million, down over 70% from $1.6 billion before reorganisation. Management reaffirmed full-year 2026 guidance of $620-635 million in revenue and $105-115 million adjusted EBITDA.